Anifrolumab, AstraZeneca Plc’s experimental treatment for lupus, has missed its primary endpoint in a study. The drug failed to meet the goal of a late-stage trial that had 373 patients. Patients in the study did not see a statistically significant reduction in disease activity compared with those who received a placebo in the yearlong study, … Continue reading “AstraZeneca’s Experimental Lupus Treatment Fails to Hit Primary Endpoint”
Biotech & Pharma
Biotech & Pharma
Insys Therapeutics Skyrockets on FDA Fast Track Designation
Shares of Insys Therapeutics were on the rise in Thursday's trading session after the company…
August 30, 2018
Biotech & Pharma
Gilead Paid $510 Million For This Drug But Sold it For Only $3 Million
It was five years ago that Gilead Sciences Inc. paid $510 million for a deal…
August 23, 2018
Biotech & Pharma
PTC Therapeutics Announces it Will Buy Agilis Biotherapeutics for $200M
It was on Thursday that PTC Therapeutics announced that it plans to acquire five-year old…
July 20, 2018
Biotech & Pharma
Sage Shares Soar After FDA Gives Green Light for This
Shares of Sage Therapeutics were exploding in Tuesday trading after the Food and Drug Administration…
June 12, 2018
Biotech & Pharma
Stryker Makes Takeover Offer for Rival Boston Scientific Corp.
It was an interesting day for medical device makers Stryker and Boston Scientific Corp. While…
June 11, 2018
Biotech & Pharma
Sanofi Responds to Roseanne’s Ambien Tweet with Epic Response
Sanofi, the maker of Ambien, wasn't taking things sitting down when Roseanne Barr blamed her…
May 30, 2018
Biotech & Pharma
FDA Says Teething Medicines Aren’t Safe for Children
This may not be the best news for parents to read who have teething children,…
May 23, 2018
Biotech & Pharma
Amgen Migraine Preventive Drug gets FDA Approval
The Food and Drug Administration has approved Amgen's drug Aimovig for the prevention of migraines.…
May 17, 2018
Biotech & Pharma
Elliott Management Makes Unsolicited Bid to Take Athenahealth Private
Athenahealth shares saw big gains on Monday after it was revealed that hedge fund Elliott…
May 7, 2018
Biotech & Pharma
Acadia Shares Fall After FDA Launches Safety Review on its Parkinson’s Disease Medication
Shares of biotech giant Acadia Pharmaceuticals were deep in the red in Wednesday trading after…
April 25, 2018
Biotech & Pharma
Merck Just Received an Upgrade from Goldman Sachs for This Reason
Shares of Merck were on the rise in Monday trading after the pharmaceutical giant received…
April 24, 2018
Biotech & Pharma
Novartis Just Made an $8.7 Billion Dollar Bet on this Gene Therapy Company
Novartis and AveXis shares saw big gains in Monday trading after it was announced that…
April 9, 2018
Biotech & Pharma
Incyte Shares Fall after Combo Drug with Merck Failed in Study
Shares of Incyte fell 20% on Friday after a combo therapy with drug giant Merck…
April 7, 2018